Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CytoDyn Inc. (OTC: CYDY).

Full DD Report for CYDY

You must become a subscriber to view this report.


Recent News from (OTC: CYDY)

NetworkNewsBreaks - CytoDyn Inc. (CYDY) to Develop PRO 140 as Therapy for Triple-Negative Breast Cancer
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning detailed its plan to develop PRO 140 (leronlimab) as a therapy for metastatic triple-negative breast cancer. Per the update, previously announced findings from preclinical studies showed the ability of PRO 140 to block human breast ...
Source: NetworkNewsWire
Date: September, 05 2018 08:30
CytoDyn Announces Plan to Develop PRO 140 for Metastatic Triple-Negative Breast Cancer as Initial Oncology Indication
VANCOUVER, Washington, Sept. 05, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces its plan to develop PRO 140 (leronlimab) as a therapy for triple-negative brea...
Source: GlobeNewswire
Date: September, 05 2018 06:00
NetworkNewsBreaks - Why CytoDyn Inc. (CYDY) is "One to Watch"
Biotechnology company CytoDyn (OTCQB: CYDY) is focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. A recent article discussing the company reads: “Th...
Source: NetworkNewsWire
Date: September, 04 2018 15:15
SeriousTraders Puts Spotlight on ATHC, AHELF, CIIX, CYDY, DNAX, FNNZF, FRSX, FTSSF, GRBX, LXRP, MCOA, NETE, NUGL, NUGS, REFG, PFSF, PHVAF, PRVCF, SGMD, SNNVF, TGODF, TMSR, TVTV, YGYI and ZNGY
Every month, SeriousTraders issues a newsletter to its subscribers jam packed with specialized articles; you won't miss an opportunity to hone your trading edge. Here are the 26 companies featured this month: Accelerated Technologies Holding Corp. (OTC: ATHC) is a full-service end-to-end...
Source: NetworkNewsWire
Date: August, 30 2018 08:55
NetworkNewsBreaks - CytoDyn Inc. (CYDY) Enters Definitive Agreement to Acquire ProstaGene, Announces Key Addition to Leadership Team
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced its entry into a definitive agreement to acquire privately held ProstaGene, LLC. The company also confirmed that Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and CEO of ProstaGene, will join CytoD...
Source: NetworkNewsWire
Date: August, 28 2018 08:30
CytoDyn signs definitive agreement to acquire Prostagene
CytoDyn ( OTCQB:CYDY ) signs a definitive agreement to acquire privately held ProstaGene, LLC. CytoDyn also confirms that Richard G. Pestell, Founder and CEO of ProstaGene, will join CytoDyn as Interim Chief Medical Officer. More news on: CytoDyn Inc., Healthcare stocks news, Read mo...
Source: SeekingAlpha
Date: August, 28 2018 06:47
CytoDyn Signs Definitive Agreement to Acquire ProstaGene; Founder and CEO Dr. Richard Pestell to Join CytoDyn as Interim Chief Medical Officer
VANCOUVER, Washington, Aug. 28, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, including treatment of HIV and cancer, announces the signing of a definitive agreement to...
Source: GlobeNewswire
Date: August, 28 2018 06:00
NetworkNewsBreaks - CytoDyn Inc. (CYDY) President and CEO Discusses Company Research in Interview on Uptick Newswire's "Stock Day" Podcast
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that the company’s president and CEO Nader Pourhassan was interviewed on Uptick Newswire’s “Stock Day” Podcast. Among other highlights, Pourhassan discussed the company’s main product, a human...
Source: NetworkNewsWire
Date: August, 27 2018 09:00
CytoDyn, Inc.'s President and CEO, Nader Pourhassan, Ph.D., Discusses Company Research with Everett Jolly on Uptick Newswire's "Stock Day" Podcast
PHOENIX, Aug. 27, 2018 (GLOBE NEWSWIRE) -- CytoDyn, Inc. (OTCQB:CYDY), (the “Company”) announced President and CEO Nader Pourhassan’s interview on Uptick Newswire’s “Stock Day” Podcast. Everett Jolly invited a company for the very first time to t...
Source: GlobeNewswire
Date: August, 27 2018 07:30
NetworkNewsBreaks - CytoDyn Inc. (CYDY) Developing Therapeutic Anti-Viral Agent as Potential Alternative to Current HIV Treatment Options
Biotechnology company CytoDyn (OTCQB: CYDY) remains focused on the development of its new anti-HIV treatment, PRO 140. An article discussing the company’s therapeutic anti-viral agent reads: “The development of PRO 140 is of particular interest, because it could allow people livi...
Source: NetworkNewsWire
Date: August, 23 2018 10:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.540.510.540.51113,297
2018-12-130.53550.520.550.52248,102
2018-12-120.550.540.56450.525248,199
2018-12-110.58020.540.58020.53251,576
2018-12-100.600.570.600.5771,119

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1410,442113,2979.2165Cover
2018-12-1342,455248,10217.1119Cover
2018-12-12104,501248,19942.1037Short
2018-12-11196,102251,57677.9494Short
2018-12-1024,03571,11933.7955Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CYDY.


About CytoDyn Inc. (OTC: CYDY)

Logo for CytoDyn Inc. (OTC: CYDY)

CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn s lead product candidate, PRO , has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.

 

Contact Information

 

 

Current Management

  • Nader Z, Pourhassan, Ph.D. / CEO, President
  • Michael D. Mulholland / CFO, Treasurer, Corporate Secretary
  • Denis R. Burger, Ph.D. / Chief Scientific Officer
  • Tracie L. Melchior, CPA / Director of Accounting
  • Anthony D. Caracciolo / Executive Chairman
  • Gregory A Gould, CPA / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Carl C. Dockery / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Scott Kelly / Independent Director
    • Scott has a Bachelor of Commerce degree from Royal Roads University. He has been involved as an officer and consultant to junior exploration companies since and was the VP Finance of Pediment Gold Corp. until it was taken over by Argonaut Gold Inc. in . Scott is currently the CFO of Ely Gold amp Minerals Inc.
  • A. Bruce Montgomery, M.D. / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Jordan G. Naydenov / Independent Director, Compensation Committee Member, Nominating Committee Member
  • Denis R. Burger, Ph.D. /
  • Nader Z, Pourhassan, Ph.D. /

Current Share Structure

  • Market Cap: $143,308,144 - 03/15/2018
  • Authorized: 375,000,000 - 03/14/2018
  • Issue and Outstanding: 208,904,000 - 03/14/2018
  • Float: 86,010,697 - 09/30/2017

 


Recent Filings from (OTC: CYDY)

Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 08 2018
Proxy soliciting materials. Revised preliminary material
Filing Type: PRER14AFiling Source: edgar
Filing Date: May, 04 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Amendment to a previously filed SC TO-I
Filing Type: SC TO-I/AFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 23 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: March, 23 2018

 

 


Daily Technical Chart for (OTC: CYDY)

Daily Technical Chart for (OTC: CYDY)


Stay tuned for daily updates and more on (OTC: CYDY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CYDY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CYDY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CYDY and does not buy, sell, or trade any shares of CYDY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/